--- title: "Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge" type: "News" locale: "en" url: "https://longbridge.com/en/news/281716307.md" description: "Lepu Biopharma (SEHK:2157) has reported a significant earnings turnaround, moving from a net loss to a net income of CNY 261.36 million for the full year 2025, with sales reaching CNY 934.87 million. The company's share price has surged, with a 30-day return of 40.09% and a year-to-date return of 23.49%. However, it trades at a high P/E ratio of 37.3x, which is considered overvalued compared to its estimated fair level of 3.2x. Investors are advised to weigh the optimism against potential risks as the company relies on a pipeline still in clinical trials." datetime: "2026-04-05T17:43:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281716307.md) - [en](https://longbridge.com/en/news/281716307.md) - [zh-HK](https://longbridge.com/zh-HK/news/281716307.md) --- # Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge ## Earnings turnaround puts Lepu Biopharma back on investors’ radar Lepu Biopharma (SEHK:2157) has drawn fresh attention after reporting full year 2025 results that shifted from a net loss to net income of CNY 261.36 million, with sales of CNY 934.87 million. The company also moved from a basic loss per share of CNY 0.24 to basic earnings per share of CNY 0.15 from continuing operations, a change that gives investors new financial data points to assess the stock. See our latest analysis for Lepu Biopharma. The earnings turnaround has arrived alongside strong momentum in the share price, with a 30 day share price return of 40.09% and a year to date share price return of 23.49%. The 1 year total shareholder return of 54.52% suggests sentiment has improved over both shorter and longer horizons. If Lepu Biopharma’s move back into profit has caught your attention, it can be useful to compare it with other healthcare names using our screener for 125 healthcare AI stocks With Lepu Biopharma back in profit, rapid revenue growth and a recent share price surge, the key question now is simple: are investors still getting in at a discount, or is the market already pricing in future growth? ## Price to earnings of 37.3x: Is it justified? Lepu Biopharma trades on a P/E of 37.3x, which the data suggests looks cheaper than many biotech peers, yet still expensive against its own estimated fair level. The P/E ratio compares the current share price to earnings per share, so a higher figure often reflects stronger profit expectations or a willingness to pay more for each unit of earnings. For a biotech name that has only recently moved into profit, a 37.3x P/E indicates investors are paying a premium for those earnings. Compared with the Asian Biotechs industry average of 39.2x and a peer average of 56.6x, Lepu Biopharma screens as good value on a relative basis. However, against the estimated fair P/E of 3.2x, its current multiple looks very rich, a level the market could move toward if sentiment or earnings expectations cool. Explore the SWS fair ratio for Lepu Biopharma **Result: Price-to-earnings of 37.3x (OVERVALUED)** However, the high P/E and heavy reliance on a pipeline still in clinical trials mean that any setback or slower-than-expected uptake could quickly cool this enthusiasm. Find out about the key risks to this Lepu Biopharma narrative. ## Next Steps With sentiment clearly split between optimism and caution, it makes sense to look at the numbers for yourself and decide quickly where you stand. To see both sides of the story in one place, review the 2 key rewards and 2 important warning signs. ## Looking for more investment ideas? If Lepu Biopharma is already on your radar, do not stop there. Using a few focused screens can help you quickly spot other opportunities that fit your style. - Zero in on potential bargains by scanning companies that currently look mispriced on quality and valuation through our 245 high quality undervalued stocks. - Build a steadier core for your portfolio by focusing on companies with healthier finances via our solid balance sheet and fundamentals stocks screener (385 results). - Hunt for future standouts before they become widely followed by checking the screener containing 591 high quality undiscovered gems. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [02157.HK](https://longbridge.com/en/quote/02157.HK.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)